Labcorp Holdings Inc. (LH) Hit a 52 Week High, Can the Run Continue?

Labcorp Holdings (LH) recently hit a 52-week high of $283.47, marking a 22.1% year-to-date gain and significantly outperforming its sector and industry. This strong performance is driven by a consistent record of positive earnings surprises, including a recent beat on EPS and revenue, alongside robust projected EPS growth of 11.87% for the current fiscal year and 9.74% for the next. While trading at a slight valuation premium to its peers, the company maintains a Zacks Rank #2 (Buy) and strong Zacks Style Scores for Value and overall VGM, indicating potential for continued upside within a favorable Medical Services industry landscape.

Analysis

Labcorp Holdings (LH) has demonstrated significant market outperformance, reaching a new 52-week high of $283.47 and delivering a 22.1% year-to-date gain, which starkly contrasts with the negative returns of the broader Zacks Medical sector (-2%) and its specific industry (-0.6%). This momentum is underpinned by a consistent track record of financial execution, evidenced by four consecutive quarters of positive earnings surprises. In its most recent report, Labcorp posted an EPS of $4.35, exceeding the consensus estimate of $4.14, and surpassed revenue expectations by 1.14%. The forward-looking outlook remains robust, with consensus estimates projecting double-digit EPS growth of 11.87% for the current fiscal year and 9.74% for the next. While the stock trades at a slight premium to its industry on a forward P/E basis (17.2X vs. 16.7X) and on a price-to-cash flow basis (12.5X vs. 10.1X), its supportive metrics, including a PEG ratio of 1.79 and a top-tier Zacks Value Score of 'A', suggest the valuation is backed by fundamentals. This view is further reinforced by a Zacks Rank of #2 (Buy), indicating a positive trend in earnings estimate revisions within a favorable industry context, as the Medical Services industry ranks in the top 41% of the Zacks universe.

Key Decisions for Investors

• Given Labcorp's consistent earnings beats, strong forward growth estimates, and a Zacks #2 (Buy) rating, investors could consider the stock a viable holding or new long position, as fundamental strength appears to support its recent price appreciation.
• Investors should remain mindful of the premium valuation, with its forward P/E of 17.2X and P/CF of 12.5X exceeding peer averages, and monitor for any significant expansion of this premium that could signal the stock is becoming overextended.
• For those seeking relative value within the attractive Medical Services sector, peer Solventum Corporation (SOLV) warrants consideration due to its #1 (Strong Buy) rating and more compelling valuation multiples, including a forward P/E of 12.47X.